HZNP Horizon Pharma plc

15.49
+0  (1%)
Previous Close 15.35
Open 15.36
Price To book 1.96
Market Cap 2.51B
Shares 162,334,000
Volume 1,708,763
Short Ratio 4.31
Av. Daily Volume 2,724,890

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 17777925
  2. 8-K - Current report 17774562
  3. CT ORDER - Confidential treatment order 17739051
  4. DEF 14A - Other definitive proxy statements 17734329
  5. 8-K - Current report 17723410

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 8, 2016 - primary endpoint not met.
ACTIMMUNE
Friedreich's Ataxia (FA)

Latest News

  1. Horizon Pharma Plc breached its 50 day moving average in a Bullish Manner : HZNP-US : April 28, 2017
  2. The 7 Most Expensive Prescription Drugs in the World
  3. Which Drugmakers Will Rock The Sector In Q1?
  4. Horizon Pharma plc to Host First-Quarter 2017 Conference Call and Webcast on May 8, 2017
  5. Horizon Pharma plc Named One of the Best Workplaces in Health Care by Great Place to Work® and Fortune Magazine
  6. Horizon Pharma plc Named to the Crain’s Chicago Business 2017 “Best Places To Work” List
  7. Bears Are Losing Their Grip on Horizon Pharma
  8. Horizon (HZNP) Down 10.2% Since Earnings Report: Can It Rebound?
  9. Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO® (naproxen/esomeprazole) Delayed Release Tablets
  10. Nuvo Pharmaceuticals™ Enters into Pennsaid® 2% License Agreement with Sayre Therapeutics PVT Ltd. for India, Sri Lanka, Bangladesh and Nepal
  11. Horizon Pharma, Inc. -- Moody's affirms Horizon Pharma at B2, raises SGL rating to SGL-1; stable outlook
  12. Horizon Pharma plc to Present Data on RAVICTI® (glycerol phenylbutyrate) Oral Liquid for Urea Cycle Disorder Patients Aged Two Months to Two Years
  13. Can Horizon Pharma (HZNP) Be a Great Stock for Value Investors?
  14. Horizon Pharma plc Announces "UCD in Common" for the Urea Cycle Disorder (UCD) Community
  15. Horizon Pharma plc Announces Urea Cycle Disorders Medical Foods and Supplements Financial Assistance Program
  16. Nuvo Pharmaceuticals™ Announces 2016 Year-End and Fourth Quarter Results
  17. Horizon Pharma Plc :HZNP-US: Earnings Analysis: Q4, 2016 By the Numbers : March 1, 2017
  18. Horizon (HZNP) Misses on Earnings in Q4, View Disappoints
  19. Horizon Pharma plc Launches RAREis™ Campaign Elevating Faces of the Rare Disease Community